Cargando…

Proteomic Analysis of a NAP1 Clostridium difficile Clinical Isolate Resistant to Metronidazole

BACKGROUND: Clostridium difficile is an anaerobic, Gram-positive bacterium that has been implicated as the leading cause of antibiotic-associated diarrhea. Metronidazole is currently the first-line treatment for mild to moderate C. difficile infections. Our laboratory isolated a strain of C. diffici...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chong, Patrick M., Lynch, Tarah, McCorrister, Stuart, Kibsey, Pamela, Miller, Mark, Gravel, Denise, Westmacott, Garrett R., Mulvey, Michael R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3882210/ https://www.ncbi.nlm.nih.gov/pubmed/24400070 http://dx.doi.org/10.1371/journal.pone.0082622

Ejemplares similares

Characterization of a Stable, Metronidazole-Resistant Clostridium difficile Clinical Isolate
por: Lynch, Tarah, et al.
Publicado: (2013)

Unbiased Proteomics Analysis Demonstrates Significant Variability in Mucosal Immune Factor Expression Depending on the Site and Method of Collection
por: Birse, Kenzie M., et al.
Publicado: (2013)

Comparison of genomes and proteomes of four whole genome-sequenced Campylobacter jejuni from different phylogenetic backgrounds
por: Clark, Clifford G., et al.
Publicado: (2018)

Proteomic Signatures of Clostridium difficile Stressed with Metronidazole, Vancomycin, or Fidaxomicin
por: Maaß, Sandra, et al.
Publicado: (2018)

Characterization of Clostridium difficile Strains in British Columbia, Canada: A Shift from NAP1 Majority (2008) to Novel Strain Types (2013) in One Region
por: Jassem, Agatha N., et al.
Publicado: (2016)

DNA Sequence Heterogeneity of Campylobacter jejuni CJIE4 Prophages and Expression of Prophage Genes
por: Clark, Clifford G., et al.
Publicado: (2014)

1651 Role of Metronidazole vs Vancomycin as Initial Therapy in Hospitalized Patients with Mild to Moderate Clostridium difficile Infection (CDI) with NAP1 vs non-NAP1 Disease
por: Dubrovskaya, Yanina, et al.
Publicado: (2014)

Clostridium difficile Enteritis With NAP7/078 Toxigenic Strain
por: Zewude, Rahel T, et al.
Publicado: (2023)

Hypervirulent Clostridium difficile Strains in Hospitalized Patients, Canada
por: Mulvey, Michael R., et al.
Publicado: (2010)

Metronidazole-triazole conjugates: Activity against Clostridium difficile and parasites
por: Jarrad, Angie M., et al.
Publicado: (2015)

Rifaximin Therapy for Patients With Metronidazole-Unresponsive Clostridium difficile Infection
por: Waqas, Muhammad, et al.
Publicado: (2022)

Detection of Antimicrobial Resistance Using Proteomics and the Comprehensive Antibiotic Resistance Database: A Case Study
por: Chen, Chih‐yu, et al.
Publicado: (2020)

Efficacy of Oral Vancomycin, Oral Metronidazole, or IV Metronidazole Prophylaxis at Reducing the Risk of Clostridium difficile Recurrence
por: O’Connell, Matthew, et al.
Publicado: (2017)

Therapeutic Success of Rifaximin for Clostridium difficile Infection Refractory to Metronidazole and Vancomycin
por: Tannous, George, et al.
Publicado: (2010)

Pregnancy associates with alterations to the host and microbial proteome in vaginal mucosa
por: Farr Zuend, Christina, et al.
Publicado: (2020)

Human Papillomavirus 16 E6 and E7 Oncoproteins Alter the Abundance of Proteins Associated with DNA Damage Response, Immune Signaling and Epidermal Differentiation
por: Dust, Kerry, et al.
Publicado: (2022)

Reconsidering the Sporulation Characteristics of Hypervirulent Clostridium difficile BI/NAP1/027
por: Burns, David A., et al.
Publicado: (2011)

First Report of Clostridium difficile NAP1/027 in a Mexican Hospital
por: Camacho-Ortiz, Adrián, et al.
Publicado: (2015)

The CJIE1 prophage of Campylobacter jejuni affects protein expression in growth media with and without bile salts
por: Clark, Clifford G, et al.
Publicado: (2014)

Effect of Metronidazole in Infants with Bowel Habit Change: Irrelative to the Clostridium difficile Colonization
por: Kim, Eun Jin, et al.
Publicado: (2017)

Correction: First Report of Clostridium difficile NAP1/027 in a Mexican Hospital
por: Camacho-Ortiz, Adrián, et al.
Publicado: (2015)

Prevalence of Hypervirulent BI/NAP1/027 Clostridium difficile Strains in Cali-Colombia
por: Rosso, Fernando, et al.
Publicado: (2017)

Mass spectrometry analysis of gut tissue in acute SIV-infection in rhesus macaques identifies early proteome alterations preceding the interferon inflammatory response
por: Berard, A. R., et al.
Publicado: (2023)

Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection
por: Dubberke, Erik R, et al.
Publicado: (2020)

The Hypervirulent Strain of Clostridium Difficile: NAP1/B1/027 - A Brief Overview
por: Fatima, Rawish, et al.
Publicado: (2019)

Treatment of Clostridium difficile infection in mice with vancomycin alone is as effective as treatment with vancomycin and metronidazole in combination
por: Erikstrup, Lise Tornvig, et al.
Publicado: (2015)

Initial Oral Vancomycin vs. Oral Vancomycin After Metronidazole for Severe Clostridium difficile Infection
por: Shah, Sunish, et al.
Publicado: (2017)

Metronidazole therapy as initial treatment of Clostridium difficile infection in patients with chronic kidney disease in Korea
por: Shin, Jaeuk, et al.
Publicado: (2019)

A meta-analysis of metronidazole and vancomycin for the treatment of Clostridium difficile infection, stratified by disease severity
por: Di, Xiuzhen, et al.
Publicado: (2015)

Defining the Vulnerable Period for Re-Establishment of Clostridium difficile Colonization after Treatment of C. difficile Infection with Oral Vancomycin or Metronidazole
por: Abujamel, Turki, et al.
Publicado: (2013)

488. Oral Vancomycin Plus Intravenous Metronidazole for Severe Clostridium difficile Infection in Critically Ill Patients
por: Vega, Ana, et al.
Publicado: (2018)

Chlamydial Protease-Like Activity Factor and Type III Secreted Effectors Cooperate in Inhibition of p65 Nuclear Translocation
por: Patton, Michael John, et al.
Publicado: (2016)

Risk Factors for BI/NAP1/027 Clostridioides difficile Infections and Clinical Outcomes Compared With Non-NAP1 Strains
por: Mani, Nandita S, et al.
Publicado: (2019)

Clostridium difficile 027/BI/NAP1 Encodes a Hypertoxic and Antigenically Variable Form of TcdB
por: Lanis, Jordi M., et al.
Publicado: (2013)

Vaginal microbiome-hormonal contraceptive interactions associate with the mucosal proteome and HIV acquisition
por: Noël-Romas, Laura, et al.
Publicado: (2020)

Clostridium difficile outbreak caused by NAP1/BI/027 strain and non-027 strains in a Mexican hospital
por: Morfin-Otero, Rayo, et al.
Publicado: (2015)

Evaluation of the Xpert Clostridium difficile Assay for the Diagnosis of Clostridium difficile Infection
por: Shin, Saeam, et al.
Publicado: (2012)

Impact of subinhibitory concentrations of metronidazole on proteome of Clostridioides difficile strains with different levels of susceptibility
por: Doan, Tri-Hanh-Dung, et al.
Publicado: (2020)

Impact of the griffithsin anti-HIV microbicide and placebo gels on the rectal mucosal proteome and microbiome in non-human primates
por: Girard, Lauren, et al.
Publicado: (2018)

MS-H: A Novel Proteomic Approach to Isolate and Type the E. coli H Antigen Using Membrane Filtration and Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
por: Cheng, Keding, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_5lm1tusvl3bgercc97c54pqs8v